Inc. ("WuXi Biologics" or "the Group", stock code: 2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) service company offering end-to-end solutions for ...

ADMA Biologics, Inc. has a 52 week low of $5.88 and a 52 week high of $23.64. The stock has a market cap of $4.36 billion, a P/E ratio of 65.82 and a beta of 0.60.

1 Day 2269 14.38% DJIA -1.30% S&P 500 -1.39% Health Care/Life Sciences 1.12% ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

BIOVECTRA, a part of Agilent Technologies Inc., is a leading North American CDMO specializing in biologics, mRNA therapeutics, and complex chemistry, proudly announces it is the recipient of the ...

Leader in Green CRDMO to drive innovation for a healthier future SHANGHAI, March 10, 2025 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development ...

India's Syngene International on Monday said it has acquired its first biologics facility in the United States from Emergent Manufacturing Operations Baltimore, a unit of Emergent BioSolutions, for ...

We've identified the following companies as similar to WuXi Biologics (Cayman) Inc. because they operate in a related industry or sector. We also considered size, growth, and various financial metrics ...

Welcome to Lab Dish, a new First Opinion column on regenerative medicine from Paul Knoepfler. With all the uncertainties surrounding the Food and Drug Administration under Trump 2.0, the recent ...